Zykadia (ceritinib)
- Region
- 🇪🇺 EU
- Active substance
- ceritinib
- Company
- Novartis Europharm Limited
- Status
- Authorised
- Therapeutic area
- Carcinoma, Non-Small-Cell Lung
- CHMP opinion
- Thu 26 Feb 2015
- EU approval
- Wed 06 May 2015
- Application
- EMEA/H/C/003819
- ATC
- L01XE
- Official record
- www.ema.europa.eu
Indication
Zykadia is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) previously treated with crizotinib.
Regulatory milestones
No milestones recorded in the last year.
Follow Zykadia
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.